In November 2007, Bayer AG suspended worldwide sales of Trasylol, a clotting drug using during heart surgery to prevent bleeding, following a request from the U.S. Food and Drug Administration to remove the drug from the American market for safety reasons.
"In addition, in February 2007, a study published in the Journal of the American Medical Association found patients on the drug were at greater risk of dying over the next five years than those given two other medications. The same researchers had linked the drug to an increased risk of kidney failure, heart failure and stroke in a study published in 2006." "Our present findings deal with death," one of the JAMA study's authors, Dr. Dennis T. Mangano, said at the time. Mangano, director of the Ischemia Research and Education Foundation, a California-based nonprofit group, said that "the death rate for aprotinin patients far outstrips that for the other two drugs." In interviews with CBS 60 Minutes, Researchers expressed the opinion that had the drug been pulled front the market earlier, over 22,000 deaths could have been avoided.
Patients who were given the blood clotting agent Trasylol during heart bypass, heart valve replacement, or other cardiac procedures were deemed by the FDA more likely to die from complications than patients who were given similar, competing drugs. The maker of Trasylol, Bayer AG, suspended sales of the drug that more than 4.5 million people had been administered worldwide. Nearly one third of the users were in the United States during the 14 years that it was available in the US market.
Trasylol was found to contribute to:
If you or a family member have suffered adverse side effects after using Trasylol, you may be eligible to file a claim. Klein Frank, P.C. has years of experience successfully representing clients in personal injury cases involving dangerous and defective prescription drugs. To schedule a consultation with a Boulder personal injury attorney, please contact us at (303) 622-3876.